WO2003040187A1 - Anticorps monoclonaux du virus de l'hepatite e ou fragments liants en provenant et utilisation correspondante - Google Patents

Anticorps monoclonaux du virus de l'hepatite e ou fragments liants en provenant et utilisation correspondante Download PDF

Info

Publication number
WO2003040187A1
WO2003040187A1 PCT/CN2002/000797 CN0200797W WO03040187A1 WO 2003040187 A1 WO2003040187 A1 WO 2003040187A1 CN 0200797 W CN0200797 W CN 0200797W WO 03040187 A1 WO03040187 A1 WO 03040187A1
Authority
WO
WIPO (PCT)
Prior art keywords
present
monoclonal antibodies
hepatitis
polypeptides
recombination
Prior art date
Application number
PCT/CN2002/000797
Other languages
English (en)
French (fr)
Inventor
Ningshao Xia
Jun Zhang
Ying Gu
Shaowei Li
Shengxiang Ge
Zhiqiang He
Original Assignee
Yang Sheng Tang Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4672637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO2003040187(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yang Sheng Tang Company Limited filed Critical Yang Sheng Tang Company Limited
Priority to JP2003542232A priority Critical patent/JP2005524386A/ja
Priority to MXPA04004321A priority patent/MXPA04004321A/es
Priority to AU2002349727A priority patent/AU2002349727B2/en
Priority to US10/495,091 priority patent/US7786264B2/en
Priority to BR122015016384A priority patent/BR122015016384B8/pt
Priority to EP02781056.3A priority patent/EP1452541B2/en
Priority to BRPI0214188A priority patent/BRPI0214188B8/pt
Publication of WO2003040187A1 publication Critical patent/WO2003040187A1/zh
Priority to US12/433,497 priority patent/US9428554B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
PCT/CN2002/000797 2001-11-08 2002-11-08 Anticorps monoclonaux du virus de l'hepatite e ou fragments liants en provenant et utilisation correspondante WO2003040187A1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
JP2003542232A JP2005524386A (ja) 2001-11-08 2002-11-08 抗ｅ型肝炎ウイルスモノクローナル抗体、又は結合性を有するそのフラグメント、及びそれらの使用
MXPA04004321A MXPA04004321A (es) 2001-11-08 2002-11-08 Anticuerpo monoclonal contra virus de hepatitis e o su fragmento con actividad de enlace y uso del mismo.
AU2002349727A AU2002349727B2 (en) 2001-11-08 2002-11-08 Hepatitis E virus monoclonal antibodies or the binding fragments of it and the use thereof
US10/495,091 US7786264B2 (en) 2001-11-08 2002-11-08 Monoclonal antibody against hepatitis E virus or its fragment with binding activity and use thereof
BR122015016384A BR122015016384B8 (pt) 2001-11-08 2002-11-08 polipeptídio recombinante ou isolado, molécula de ácido nucléico, kit de diagnóstico para detectar a infecção pelo vírus da hepatite e, composição de vacina, composição farmacêutica, vetor de expressão recombinante, célula hospedeira transformada e uso do polipeptídeo recombinante ou isolado
EP02781056.3A EP1452541B2 (en) 2001-11-08 2002-11-08 Hepatitis e virus monoclonal antibodies or the binding fragments of it and the use thereof
BRPI0214188A BRPI0214188B8 (pt) 2001-11-08 2002-11-08 anticorpo ou fragmento do mesmo, molécula de ácido nucléico, uso do anticorpo monoclonal ou fragmento do mesmo, kit de diagnóstico, composição farmacêutica, vetor de expressão recombinante, célula hospedeira transformada com o vetor de expressão recombinante e método para detectar o antígeno do vírus da hepatite e ou o anticorpo contra o vírus da hepatite e em uma amostra
US12/433,497 US9428554B2 (en) 2001-11-08 2009-04-30 Monoclonal antibody against hepatitis E virus or its fragment with binding activity and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN01134643 2001-11-08
CN01134643.4 2001-11-08

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US10495091 A-371-Of-International 2002-11-08
US12/433,497 Division US9428554B2 (en) 2001-11-08 2009-04-30 Monoclonal antibody against hepatitis E virus or its fragment with binding activity and use thereof

Publications (1)

Publication Number Publication Date
WO2003040187A1 true WO2003040187A1 (fr) 2003-05-15

Family

ID=4672637

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2002/000797 WO2003040187A1 (fr) 2001-11-08 2002-11-08 Anticorps monoclonaux du virus de l'hepatite e ou fragments liants en provenant et utilisation correspondante

Country Status (9)

Country Link
US (2) US7786264B2 (zh)
EP (2) EP2322625B8 (zh)
JP (3) JP2005524386A (zh)
KR (1) KR101020256B1 (zh)
CN (1) CN100339395C (zh)
AU (1) AU2002349727B2 (zh)
BR (2) BRPI0214188B8 (zh)
MX (1) MXPA04004321A (zh)
WO (1) WO2003040187A1 (zh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110021748A1 (en) * 2009-02-10 2011-01-27 Wayne State University Non-Natural Peptides as Models for the Development of Antibiotics
CN1850855B (zh) * 2006-05-26 2012-08-29 厦门大学 用于免疫或制备单克隆抗体的方法和组合物
CN110412267A (zh) * 2018-04-28 2019-11-05 洛阳普莱柯万泰生物技术有限公司 犬副流感病毒单克隆抗体及其应用

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005524386A (ja) * 2001-11-08 2005-08-18 ▲養▼生堂有限公司 抗ｅ型肝炎ウイルスモノクローナル抗体、又は結合性を有するそのフラグメント、及びそれらの使用
US8263345B2 (en) * 2006-12-14 2012-09-11 Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. Method for preparing standardized serum mixture for determining allergen potency and the use thereof
AR070141A1 (es) * 2008-01-23 2010-03-17 Glenmark Pharmaceuticals Sa Anticuerpos humanizados especificos para el factor von willebrand
JP5297734B2 (ja) * 2008-09-17 2013-09-25 株式会社Ｎｂｃメッシュテック スギ花粉アレルゲンへの結合能を有するペプチド
MX338932B (es) 2010-03-12 2016-05-06 Immunogen Inc Moleculas de union cd37 y sus inmunoconjugados.
MX2013011385A (es) 2011-04-01 2014-03-13 Immunogen Inc Moleculas de union a cd37 y sus inmunoconjugados.
EP2716661B1 (en) * 2011-06-01 2018-03-07 Xiamen University Fusion protein comprising diphtheria toxin non-toxic mutant crm197 or fragment thereof
WO2014126871A1 (en) * 2013-02-12 2014-08-21 Bristol-Myers Squibb Company Tangential flow filtration based protein refolding methods
CN105445463A (zh) * 2014-09-25 2016-03-30 苏州新波生物技术有限公司 一种戊肝IgG抗体检测试剂盒及其制备方法和应用
US20170000900A1 (en) 2015-06-08 2017-01-05 Immunogen, Inc. Anti-cd37 immunoconjugate and anti-cd20 antibody combinations
MA42706A (fr) 2015-08-28 2021-04-14 Debiopharm Int Sa Anticorps et dosages pour la détection de cd37
US11278629B2 (en) 2016-11-02 2022-03-22 Debiopharm International, S.A. Methods for improving anti-CD37 immunoconjugate therapy
KR101940806B1 (ko) * 2017-04-21 2019-01-21 (주)웅비식품 포장김 절단기
US20210269510A1 (en) * 2018-07-10 2021-09-02 Inserm (Institut National De La Santè Et De La Recherch Médicale Antibodies having specificity for the orf2i protein of hepatitis e virus and uses thereof for diagnostic purposes
US20210324049A1 (en) * 2018-07-10 2021-10-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies having specificity for the orf2i protein of hepatitis e virus and uses thereof for diagnostic purposes
CN109913424B (zh) * 2019-03-28 2020-10-27 浙江大学 一种包含戊型肝炎病毒复制子的人肝癌细胞系、应用及构建方法
GB201904328D0 (en) * 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
CN117730255A (zh) * 2021-07-06 2024-03-19 株式会社先端生命科学研究所 E型肝炎病毒感染的检测方法、e型肝炎病毒感染检测用抗原多肽和试剂盒
WO2023174976A1 (en) 2022-03-16 2023-09-21 Universität Zu Lübeck Broadly neutralizing antibodies against hepatitis e virus
CN114957411B (zh) * 2022-05-25 2023-08-18 徐州医科大学 一种正戊型肝病毒属基因c1型病毒orf2重组蛋白及其制备方法和应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014116A1 (en) * 1992-01-17 1993-07-22 Genelabs Technologies, Inc. Hepatitis e virus peptide antigens and antibodies
WO1995017501A1 (en) * 1993-12-22 1995-06-29 Abbott Laboratories Monoclonal antibodies against hev orf-2 and methods for using same
US5667966A (en) * 1993-12-22 1997-09-16 Abbott Laboratories Mouse monoclonal antibodies to Hepatitis E virus and methods for using same
US5830636A (en) * 1993-12-22 1998-11-03 Abbott Laboratories HEV orf-2 monoclonal antibodies and methods for using same
CN1345775A (zh) * 2000-09-30 2002-04-24 养生堂有限公司 用于预防、诊断及治疗戊型肝炎病毒的多肽,及它们作为诊断试剂和疫苗

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4470925A (en) 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4474493A (en) 1982-09-09 1984-10-02 Modular Systems, Inc. Dowel fastener and joints including same
US5686239A (en) 1988-06-17 1997-11-11 Genelabs Technologies, Inc. Hepatitis E virus peptides and methods
US5741490A (en) 1988-06-17 1998-04-21 Genelabs Technologies, Inc. Hepatitis E virus vaccine and method
US6291641B1 (en) * 1988-06-17 2001-09-18 Genelabs Technologies, Inc. Hepatitis E virus antigens and uses therefor
US5219990A (en) * 1991-01-28 1993-06-15 Biogen, Inc. Papillomavirus e2 trans-activation repressors
JP2908107B2 (ja) 1992-03-19 1999-06-21 株式会社日立製作所 放射性廃棄物用固化材及び放射性廃棄物の処理方法
WO1994006913A2 (en) * 1992-09-18 1994-03-31 The Government Of The United States Of America As Represented By The Secretary, Department Of Healthand Human Services Recombinant proteins of a pakistani strain of hepatitis e and their use in diagnostic methods and vaccines
US5736315A (en) 1992-10-21 1998-04-07 National Institute Of Health Methods and compositions for detecting anti-hepatitis E virus activity
JP3919830B2 (ja) * 1992-11-28 2007-05-30 財団法人化学及血清療法研究所 抗ネコヘルペスウイルス−１組換え抗体および該抗体をコードする遺伝子断片
SG95574A1 (en) * 1993-09-24 2003-04-23 Macfarlane Burnet Ct For Medic Immunoreactive antigens of hepatitia e virus
JP3504963B2 (ja) 1993-10-22 2004-03-08 智靖 羅 抗ヒト高親和性ＩｇＥ受容体モノクローナル抗体に係るアミノ酸配列をコードするＤＮＡ断片
US5830635A (en) * 1995-03-31 1998-11-03 Agnello; Vincent Method of detecting hepatitis C virus in tissues
WO2001040270A2 (en) 1999-12-01 2001-06-07 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services A major neutralization site of hepatitis e virus and use of this neutralization site in methods of vaccination and in methods of screening for neutralizing antibodies
CA2405084C (en) * 2000-04-07 2011-06-14 Howard A. Fields Neutralizing immunogenic hev polypeptides
JP2005524386A (ja) * 2001-11-08 2005-08-18 ▲養▼生堂有限公司 抗ｅ型肝炎ウイルスモノクローナル抗体、又は結合性を有するそのフラグメント、及びそれらの使用
JP2010053113A (ja) 2008-08-26 2010-03-11 Sadanao Namiki 薬物輸送に利用できる自己会合型磁性脂質ナノ粒子、及びその製造方法
JP5264792B2 (ja) 2010-01-25 2013-08-14 三菱電機株式会社 プレート式熱交換器

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993014116A1 (en) * 1992-01-17 1993-07-22 Genelabs Technologies, Inc. Hepatitis e virus peptide antigens and antibodies
WO1995017501A1 (en) * 1993-12-22 1995-06-29 Abbott Laboratories Monoclonal antibodies against hev orf-2 and methods for using same
US5667966A (en) * 1993-12-22 1997-09-16 Abbott Laboratories Mouse monoclonal antibodies to Hepatitis E virus and methods for using same
US5830636A (en) * 1993-12-22 1998-11-03 Abbott Laboratories HEV orf-2 monoclonal antibodies and methods for using same
CN1345775A (zh) * 2000-09-30 2002-04-24 养生堂有限公司 用于预防、诊断及治疗戊型肝炎病毒的多肽,及它们作为诊断试剂和疫苗

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BHAT T.N. ET AL.: "Bound water molecules and conformational stabilization help mediate an antigen-antibody association", PROC. NATL. ACAD. SCI. USA, vol. 91, no. 3, 1994, pages 1089 - 1093, XP001199897 *
BRADY R.I. ET AL.: "Crystallization and preliminary X-ray diffraction study of a chimaeric fab' fragment of antibody binding tumour cells", J. MOL. BIOL., vol. 219, no. 4, 1991, pages 603 - 604, XP000645021 *
CZERWINSKI M. AND USNARSKA: "Molecular characterization of mouse monoclonal antibody BIII.136 and the epitope recognized by the antibody in human band 3 protein", HYBRIDOMA, vol. 14, no. 3, 1995, pages 217 - 223, XP008034960 *
DATABASE GENBANK [online] 1 April 1993 (1993-04-01), "Immunoglobulin variable region, (mus musculus domesticus)", XP002992556, Database accession no. (CAA80048) *
DATABASE GENBANK [online] 26 January 1999 (1999-01-26), "Structural protein 2 (hepatitis E virus)", XP002992558, Database accession no. (AAD09445) *
DATABASE GENBANK [online] 3 February 1999 (1999-02-03), "ORF2 (hepatitis E virus)", XP002992557, Database accession no. (BAA01867) *
DATABASE GENBANK [online] 6 June 1998 (1998-06-06), "Immunoglobulin light chain, variable region (mus musculus)", XP002992555, Database accession no. (CAA07256) *
FRANCIS S.H. ET AL.: "Amino-acid sequence of the variable region of the heavy (alpha) chain of a mouse myeloma protein with anti-hapten activity", PROC. NATL. ACAD. SCI. USA, vol. 71, no. 4, 1974, pages 1123 - 1127, XP008034958 *
See also references of EP1452541A4 *
SHLOMCHIK M. ET AL.: "Anti-DNA antibodies from autoimmune mice arise by clonal expansion and somatic mutation", J. EXP. MED., vol. 171, no. 1, 1990, pages 265 - 292, XP001199896 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1850855B (zh) * 2006-05-26 2012-08-29 厦门大学 用于免疫或制备单克隆抗体的方法和组合物
US20110021748A1 (en) * 2009-02-10 2011-01-27 Wayne State University Non-Natural Peptides as Models for the Development of Antibiotics
US8362203B2 (en) * 2009-02-10 2013-01-29 Wayne State University Non-natural peptides as models for the development of antibiotics
CN110412267A (zh) * 2018-04-28 2019-11-05 洛阳普莱柯万泰生物技术有限公司 犬副流感病毒单克隆抗体及其应用
CN110412267B (zh) * 2018-04-28 2023-04-11 洛阳普泰生物技术有限公司 犬副流感病毒单克隆抗体及其应用

Also Published As

Publication number Publication date
US7786264B2 (en) 2010-08-31
JP2005524386A (ja) 2005-08-18
JP2010213693A (ja) 2010-09-30
MXPA04004321A (es) 2004-08-11
US9428554B2 (en) 2016-08-30
US20060233822A1 (en) 2006-10-19
JP5341799B2 (ja) 2013-11-13
CN100339395C (zh) 2007-09-26
EP1452541A1 (en) 2004-09-01
EP2322625B8 (en) 2016-02-24
KR20050044384A (ko) 2005-05-12
EP1452541B2 (en) 2015-06-17
EP2322625A1 (en) 2011-05-18
BR122015016384B8 (pt) 2021-07-27
JP6016699B2 (ja) 2016-10-26
BRPI0214188B1 (pt) 2016-08-02
EP1452541A4 (en) 2005-07-20
EP1452541B1 (en) 2012-06-20
JP2013226136A (ja) 2013-11-07
US20100003281A1 (en) 2010-01-07
KR101020256B1 (ko) 2011-03-08
AU2002349727B2 (en) 2008-10-16
BRPI0214188B8 (pt) 2021-05-25
EP2322625B1 (en) 2016-01-06
CN1610697A (zh) 2005-04-27
BR0214188A (pt) 2004-09-14
BR122015016384B1 (pt) 2017-02-07

Similar Documents

Publication Publication Date Title
WO2003040187A1 (fr) Anticorps monoclonaux du virus de l'hepatite e ou fragments liants en provenant et utilisation correspondante
WO2002000692A3 (en) Pd-l2 molecules: pd-1 ligands and uses therefor
WO2005056600A3 (en) Monoclonal antibodies that bind or neutralize dengue virus
WO2003070760A3 (en) Anti-amyloid beta antibodies and their use
DK0835315T3 (da) Vaccine til porcint reproduktivt og respiratorisk syndrom virus
ATE371373T1 (de) Durch polynukleinsäuren vom reproduktiven und respiratorischen syndromvirus des schweines kodierte proteine
WO2002053703A3 (en) Aav2 vectors and methods
WO2007002261A3 (en) IL-1β BINDING ANTIBODIES AND FRAGMENTS THEREOF
WO2001031019A3 (en) Neisserial antigenic peptides
JP2006526414A5 (zh)
NZ503763A (en) Antigenic compositions and vaccines comprising a high molecular weight (HMW) protein of Clamydia for therapeutic and prophylactic use
WO2005016132A3 (en) Diagnostics for sars virus
EP2298793A3 (en) Polypeptide fragments of hepatitis E virus, vaccine composition comprising said fragments and diagnostic kits
WO2001021807A8 (en) Hepatitis c virus envelope two protein (e2) which lacks all or part of the hypervariable region one (hvr1), corresponding nucleic acids, chimeric viruses and uses thereof
WO2005030793A3 (en) Antibodies which bind human cxcr3
WO2003087138A3 (en) Methods for identifying polypeptide factors interacting with rna
CA2327353A1 (en) Structural proteins of fish pancreatic disease virus and uses thereof
WO2001055353A3 (en) Recombinant attenuation of prrsv
WO2001049712A3 (en) Vaccine against isav (infectious salmon anaemia virus)
CA2491726A1 (en) Feline infectious peritonitis vaccine
WO2001046696A3 (en) Methods and compositions for detecting hepatitis e virus
WO1998042847A3 (de) Papillomvirus-hauptcapsid-proteins und deren verwendung in diagnose, therapie und vakzinierung
WO2002070559A3 (en) Nuclear hormone receptor ligand binding domains
WO2001014414A3 (en) Human abc2 transporter and uses thereof
WO2001036635A3 (en) Neurite outgrowth-promoting factor homologue and nucleic acids encoding same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 597/KOLNP/2004

Country of ref document: IN

Ref document number: PA/a/2004/004321

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2002781056

Country of ref document: EP

Ref document number: 20028222180

Country of ref document: CN

Ref document number: 1020047007046

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: 2003542232

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002349727

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2002781056

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2006233822

Country of ref document: US

Ref document number: 10495091

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10495091

Country of ref document: US